series-a
Stage
About
Kesmalea develops novel small-molecule therapeutics using its SELFTAC® platform to create oral, CNS-penetrant targeted protein degraders for the treatment of oncology and central nervous system diseases.
Explore Kesmalea's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.